Mitsui & Co, a division of the Japanese Mitsui Group, has finalised its global agreement with Monsanto to acquire all the assets save for staff related to Monsanto’s Latitude cereal seed treatment business.
The Latitude portfolio will now be distributed by Mitsui subsidiaries Certis Europe and Speiss Urania. The specialised fungicide seed treatments are used mainly used to control take all disease in wheat and barley.
Adding Latitude products to its range gives Certis the opportunity to extend the territory where it operates in seed treatment markets. Latitude will strengthen its position in Germany, the UK and elsewhere. Seed treatments have been part of the company’s distribution portfolio for over 15 years since it acquired a global licence from Janssen for the Imazalil seed treatment – Certis has maintained its registration and has expanded sales.
Mitsui recently invested in a seed treatment formulation research centre at the Japan Agro Services facility in France. The agreement with Monsanto is another significant investment in the Japanese company’s seed treatment portfolio and strengthens its position in the sector. It will also form a platform to build the Certis seed treatment offering through product licensing, innovation and development using new chemistry from Japan-based R&D companies.
Jacques Haverlant, seed treatment portfolio lead in Certis Europe, commented: “The whole company is excited at the significance of this deal for Certis and Spiess Urania. Latitude products are highly recognised speciality products with a strong brand image and, as such, fit extremely well with our corporate positioning. They also complement our existing portfolio exceptionally well and will represent an important part of our seed treatment business. The teams involved are dedicated to making it a success for us and our customers and to making the most of the great opportunities open to us, both in our existing seed treatment markets and those new to us.”